Ervebo Vaccine
Why in News?
The Ervebo vaccine is in the news because the World Health Organization (WHO) and the International Coordinating Group (ICG) have dispatched an emergency allocation of 70,000 doses to the Democratic Republic of the Congo (DRC).
Medical & Scientific Profile
- Manufacturer: Developed and manufactured by Merck Sharp & Dohme (MSD).
- Vaccine Type: It is a replication-competent, live, attenuated recombinant vesicular stomatitis virus (rVSV) vaccine.
- Mechanism: It works by utilizing a harmless vesicular stomatitis virus as a backbone, genetically engineered to express a single, safe protein from the Zaire Ebola virus.
- Safety: Because it contains only a single viral protein and not the whole virus, it cannot cause Ebola virus disease in the recipient.
- Dosage: It is administered as a single-dose injection and does not require booster shots for its approved strain.
Approvals & Targets
- Approved Indication: It is formally approved by major agencies like the U.S. FDA and the European Union for individuals 12 months of age and older.
- Primary Target: It provides over 95% proven efficacy against the Zaire ebolavirus species, historically the deadliest variant.
- Limitations: It is not officially licensed or globally recommended for routine protection against other species, such as Sudan virus or Bundibugyo virus, hence the need for the ongoing trials.
Global Stockpile & Management
- The Global Emergency Stockpile: Managed by the International Coordinating Group (ICG)—a partnership including WHO, UNICEF, MSF, and the IFRC—with funding from Gavi.
- Inventory: The stockpile aims to permanently maintain 500,000 doses of Ervebo to guarantee equitable and swift rollout to any country experiencing a sudden outbreak.
- Track Record: Ervebo has served as a cornerstone of Ebola containment, notably deployed on a massive scale during the 2018–2020 Kivu epidemic to successfully bring transmission under control.
